STAR Trial Shows Lower Toxicities from Raloxifene - National Cancer Institute
Links shared publicly online about this topic.
- 1,229total visits
STAR Trial Shows Lower Toxicities from Raloxifene - National Cancer Institute
Initial results in 2006 of the NCI-sponsored Study of Tamoxifen and Raloxifene (STAR) showed that a common osteoporosis drug, raloxifene, prevented breast cancer to the same degree, but with fewer serious side-effects, than the drug tamoxifen that had bee
View full resource at cancer.gov
Tags: Cancer, Breast Cancer, Osteoporosis, Osteoporosis Medication, Drug, Women's Health, Evista
Most Recently Shared on April 19, 2010 at 2:24 pm By:
RT @BrookeWang Raloxifene, prevents breast cancer in high risk women, with less side effects than tamoxifen http://bit.ly/bi882z #AACR10
Also Shared By:
Advertisement
NCI Media Relations
@NCIMedia
Study shows raloxifene, prevents breast cancer in high risk women, with less side effects than tamoxifen http://bit.ly/bi882z #AACR10
1 year ago...